rs112531840 - LINC02141 - NPAP1L
Magnitude 4.5 · 1 study on file
Reported associations
-
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program - Unknown journal (n.d.) · Unknown authors · PubMed 38162683
ABSTRACT: Introduction: Apparent treatment-resistant hypertension (aTRH) is characterized by the use of four or more antihypertensive (AHT) classes to achieve blood pressure (BP) control. In the current study, we conducted single-variant and gene-based analyses of aTRH among individuals from 12 Trans-Omics for Precision Medicine cohorts with whole-genome sequencing data. Methods: Cases were defined as individuals treated for hypertension (HTN) taking three different AHT classes, with average systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg, or four or more medications regardless of BP (n = 1,705). A normotensive control group was defined as individuals with BP < 140/90 mmHg (n = 22,079), not on AHT medication. A second control group comprised individuals who were treatment responsive on o
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
treatment-resistant hypertension risk and screening strategy Moderate
Genetic variant associated with 4.4-fold increased odds of apparent treatment-resistant hypertension in GWAS of 2692 participants.
Screening
-
blood pressure screening and monitoring Moderate
Genetic variant confers 4.4-fold increased risk of treatment-resistant hypertension, warranting enhanced BP surveillance.
Annual BP screening minimum; semi-annual if family history of hypertension.